MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1Kisqali plus endocrine therapy had a median OS of nearly five years (58.7 months), the longest ever reported for premenopausal women …
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor (TKI) therapies1Despite advances in chronic myeloi…
Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1Longer-term median follow-up of 40 months from the JULIE…
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms1Chronic graft-versus-host disease (GvHD) is a life-threatening complication of stem cell transplants and half of patients bec…
At Novartis, we know that our impact extends beyond the lives we touch with our medicines, and the performance we deliver for our stakeholders. We aim to have a positive impact on the communities in which we work, and build trust with society.Our flags…
In this fireside chat, Bertrand and Peter explore Microsoft’s health moonshots, COVID response and more.Video of Novartis Lecture – Why …
In this fireside chat, Bertrand and Peter explore Microsoft’s health moonshots, COVID response and more.Video of Novartis Lecture – Why …
Novartis 2020 ASH Annual Meeting Virtual PortalNovartis presence at ASH: …
This annual event gives investors and industry analysts an opportunity to meet with Novartis executives who share deep insights into the company’s growth, pipeline and strategy.We have delivered strong operational performance over the last three years …
Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographiesKey growth drivers now contributing to 48% of Innovative Medicines sales; up…